|
8:30 |
Check-in and light
breakfast |
|
9:00-9:10 |
Introduction
|
Rajiv Chopra |
|
Session I
- Enhancing output with throughput (Session chair:
Stephen Chambers) |
|
9:10-9:40 |
Developing Methods for
High Density Display of Proteins |
Niroshan Ramachandran,
Harvard Medical School, Cambridge, MA |
|
9:40-10:10 |
High-throughput,
Small-Scale Protein Expression Optimization in
Baculoviral Expression System |
Jim King,
Boehringer Ingelheim Pharmaceuticals, Ridgefield,
CT |
|
10:10-10:40 |
Automated Protein
Expression Optimization with Piccolo® |
Dawn L.
Hall, Ph.D.,
Department of Structural Biology,
Merck & Co., Inc.,
West
Point, PA |
|
10:40-11:00
|
Coffee
Break & Posters Session
|
|
Session II
- Overcoming the challenges in supplying proteins
for drug discovery; tricks and lessons learnt in
producing difficult to express proteins (Session
chair: Simon Low) |
|
11:00-11:30 |
Development of a
Selenomethionine Labeling Protocol for PCSK9
Expressed by CHO Cells in BelloCell Bioreactor |
Ing-Kae Wang,
Pfizer Global Research & Development,
Groton, CT |
|
11:30 - 12:00 |
Baculovirus
Generated Proteins for Structure Based Drug
Design: Lessons Learned |
James M. Groarke,
Protein Structure Group,
Novartis Institute for Biomedical Research,
Cambridge, MA |
|
12:00-12:15 |
A(nother) Difficult
Protein for Crystallography |
Mei Xu,
Protein Structure Group,
Novartis Institute for Biomedical Research,
Cambridge, MA
|
|
12:15-12:30 |
Improving
Production of Protein Kinases by Co-Expression
with Phosphatase |
Meggin Taylor,
Sunesis Pharmaceuticals,
South San Francisco, CA |
|
12:30-1:30 |
Lunch |
|
Session
III - New Expression Systems (Session chair: Ian
Hunt) |
|
1:30-2:00 |
Engineering
novel host strains of Kluyveromyces lactis for
heterologous protein production |
Christopher Taron,
New England Biolabs,
Beverly, MA |
|
2:00-2:30 |
Wheat
Germ Cell-free Technology for NMR-Based
Structure-Function Investigations |
John L. Markley,
University of Wisconsin, WI |
|
2:30-3:00 |
Cell-free
Protein Production in 96 Well Format |
Gregory
Michaud,
Developmental and Molecular Pathways,
Novartis Institute for
Biomedical Research,
Cambridge, MA |
|
3:00-3:15 |
Break
& Posters Session |
|
Session
IV: Panel Discussion with Audience: CRO &
Outsourcing |
|
3:15-4:45 |
Panelists:
Stephen Chambers
(Vertex), George Karam (Pfizer), Travis Stams (Novartis)
Discussion questions include:
- How many of us outsource?
- Is this a growing phenomenon?
- Can we ignore outsourcing?
- Does outsourcing really save, money and
time, and how?
- What's the rational in out-sourcing?
Increasing capacity or save money?
- Invest in automation to increase
capacity/throughput or out-sourcing?
- Is outsourcing competition or complementary?
- How do we embrace outsourcing, while at the
same time not making ourselves redundant in
the process?
- How do we distinguish our product from the
competition?
- How do we add value to our process?
- Are we ready to reinvent ourselves?
- Can proteins become a commodity?
- Are our end-users too entrenched to give us
the flexibility to re-invent ourselves?
|
|
5:00-7:00 |
Mixer & Posters Session |
